The Pulmonary Vascular Research Institute

作者: Sheila G. Haworth

DOI: 10.1086/685489

关键词:

摘要: Last year I wrote an editorial for this journal in which summarized the three primary objectives of Pulmonary Vascular Research Institute (PVRI): to improve care patients all over world who suffer from pulmonary vascular disease, facilitate and accelerate research clinical basic science encourage development new therapies. As approach end my term office as president, it seems appropriate consider road traveled ahead. We, PVRI, began a dedicated group travelers led by Ghazwan Butrous our inspirational managing director. Now we are fully fledged professional organization with permanent, stable infrastructure. We have approved published rules govern ourselves (the “Regulations PVRI”), expanded worldwide membership, superb two editors-in-chief, established program annual international congresses symposia. The congress held Rome January 2016 was largest ever held. This coming introducing third conference that will be organized by, run specifically for, younger members Committee Young Clinicians Scientists. These young people most active PVRI building strong links between colleagues Europe, Middle East, Central Asia, bodes well future PVRI. The has reached crossroads. What should priorities, how best expend time, energy, limited financial resources? The differs other organizations concerned hypertension is global, mandate help world. unsung heroes heroines those working regional task forces. Members can write helpful guidelines organize master classes e-learning materials, do, but practicalities patient understood learned locally. key here hold national smaller local meetings, several regions do now their own India about set wonderful example holding 2-day meeting next May, first day take place south country second north, both meetings webcast centers throughout India. It important each region establish its pattern events. Many developing countries share similar experiences, ideally placed them support other. There close collaboration Saudi Arabia expanded, particularly sub-Saharan Africa. also need bring continents together. Next there PVRI-sponsored on high altitude. One Bishkek, significant scientific input, Bolivia, focusing medicine at In might combine experience single meeting, preferably sea level so none participants headache hypertension! assist these endeavors offering advice expertise when appropriate, together support. wish develop networks. very challenging, others. Thus far not had resources fellowship program. give clinicians under difficult circumstances opportunity visit period while longer training excellence. Hopefully, change promise monies. Several developments been hampered past inadequacy current website. change, since website launched 2016. Two initiatives immediately feasible. First, install online consulting discussion forum. offer clinicians, isolated circumstances. interact avidly discussing cases, initiative foster interaction, friendship, networking. major modular course covering wide range topics “how diagnose treat” modules erudite “current research” modules. The curing disease fortunate include leading scientists membership. recent formation Preclinical Molecular Science Task Force interaction among scientists. successful symposium Rome, ahead sessions congress, did Paediatric Congenital Heart Disease Force. pediatric force electronically year, fostered ideal exchange ideas plan activities work continue if make any real progress. All forces, special interest, produce definitive review papers, exploited good effect. supports forces supporting special-interest manner, financing face-to-face addition electronic forms communication. advances merge interests developed worlds mutual advantage. Would more call “working groups”? Bringing drug market difficult, long, expensive business. desperately therapies, rather than having rely different formulations combinations existing drugs. target determining causative signaling pathways lie root problem. Despite greater understanding genetics pathobiology selecting promising molecules pathway(s) therapeutically complex. Clinical trials outcome uncertain. pharmaceutical industry understandably reluctant invest field because potential relatively small. anxious strengthen relationships scientists, industry, regulatory authorities. engage regularly authorities Annual Drug Development Symposium. 2014 Washington US Food Administration, London involve European Medicines Agency. continue. Perhaps surprisingly, prevention associated received little attention. Prevention schistosomiasis-associated depends public-health stratagems, usually resources. could perhaps advising pressing governmental agencies active. success preventing Eisenmenger syndrome emphasizing imperative surgical correction congenital heart infancy. ministries health realize spending precious infant cardiac surgery investment until they appreciate operating only relieve suffering remove huge economic burden community economically useful citizen. Advocacy subtle art, some others. The always aimed become pivotal center world, medicine, research, government think advice. fact, aim “one-stop shop.” experienced, learned, membership gradually moving toward goal. so, must careful compromise ethos characterizes PVRI: spirit warmth, collaboration, absence hierarchy, desire promote community, less fortunate. tradition, friendship tolerance, calendar events anticipate enjoy. It great privilege president PVRI. am grateful unfailing given me many Council Executive just beginning long journey. When you out journey Ithaka pray long, full adventures, full knowledge. … Ithaka gave wondrous voyage: without her, would out. (CP Cavafy: “Ithaka,” 154 Selected Poems, translated Evangelos Sachperoglou; Athens: Tasos Vagenas, 2003)

参考文章(133)
A A Satir, A M Hassan, M A Ahmed, A Omer, The pathology of schistosomiasis in Sudan. Tropical and geographical medicine. ,vol. 29, pp. 56- 64 ,(1977)
R. Loch Macdonald, Bryce Weir, Pathology and Pathogenesis Cerebral Vasospasm. pp. 87- 174 ,(2001) , 10.1016/B978-012464161-7/50006-8
Joachim Fandrey, Max Gassmann, Oxygen Sensing and the Activation of the Hypoxia Inducible Factor 1 (HIF-1)– Invited Article Advances in Experimental Medicine and Biology. ,vol. 648, pp. 197- 206 ,(2009) , 10.1007/978-90-481-2259-2_23
Antonio Atílio Laudanna, Vincenzo Pugliese, Roberto de Cleva, Paulo Herman, Bruno Zilberstein, William Abrão Saad, Joaquim Jose Gama Rodrigues, Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study. Hepato-gastroenterology. ,vol. 50, pp. 2028- 2030 ,(2003)
Irving Graef, Eugene Clark, Chronic Pulmonary Arteritis in Schistosomiasis Mansoni Associated with Right Ventricular Hypertrophy: Report of a Case American Journal of Pathology. ,vol. 11, pp. 693- ,(1935)
Gassmann M, Wenger Rh, OXYGEN(ES) AND THE HYPOXIA-INDUCIBLE FACTOR-1 Biological Chemistry. ,vol. 378, pp. 609- 616 ,(1997)
Adrian L. Harris, Hypoxia — a key regulatory factor in tumour growth Nature Reviews Cancer. ,vol. 2, pp. 38- 47 ,(2002) , 10.1038/NRC704
Cesar Machado, Ísis Brito, Denile Souza, Luis Cláudio Correia, Etiological frequency of pulmonary hypertension in a reference outpatient clinic in Bahia, Brazil. Arquivos Brasileiros De Cardiologia. ,vol. 93, pp. 679- 686 ,(2009) , 10.1590/S0066-782X2009001200019
Patrick H. Maxwell, Michael S. Wiesener, Gin-Wen Chang, Steven C. Clifford, Emma C. Vaux, Matthew E. Cockman, Charles C. Wykoff, Christopher W. Pugh, Eamonn R. Maher, Peter J. Ratcliffe, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature. ,vol. 399, pp. 271- 275 ,(1999) , 10.1038/20459